Whitehawk Therapeutics, Inc. financial data

Symbol
WHWK on Nasdaq
Location
Morristown, NJ
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1330% % 182%
Quick Ratio 11% % -61%
Debt-to-equity 8.1% % -68%
Return On Equity -10% % 86%
Return On Assets -9.6% % 83%
Operating Margin -754% % -185%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 47,128,362 shares 91%
Common Stock, Shares, Outstanding 47,128,362 shares 91%
Entity Public Float $24,400,000 USD -78%
Common Stock, Value, Issued $4,000 USD 100%
Weighted Average Number of Shares Outstanding, Basic 69,204,899 shares 156%
Weighted Average Number of Shares Outstanding, Diluted 69,204,899 shares 156%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $14,384,000 USD -43%
Research and Development Expense $86,289,000 USD 74%
Costs and Expenses $122,846,000 USD 35%
Operating Income (Loss) $108,462,000 USD -64%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $15,618,000 USD 75%
Earnings Per Share, Basic 0 USD/shares 43%
Earnings Per Share, Diluted 0 USD/shares 43%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $37,931,000 USD 24%
Cash, Cash Equivalents, and Short-term Investments $162,600,000 USD 160%
Accounts Receivable, after Allowance for Credit Loss, Current $0 USD -100%
Inventory, Net $0 USD -100%
Assets, Current $165,036,000 USD 113%
Property, Plant and Equipment, Net $4,000 USD -100%
Operating Lease, Right-of-Use Asset $0 USD -100%
Other Assets, Noncurrent $1,977,000 USD 30%
Assets $167,017,000 USD 95%
Accounts Payable, Current $1,633,000 USD 19%
Accrued Liabilities, Current $8,216 USD
Liabilities, Current $9,849,000 USD -38%
Operating Lease, Liability, Noncurrent $0 USD -100%
Other Liabilities, Noncurrent $0 USD -100%
Liabilities $9,849,000 USD -41%
Accumulated Other Comprehensive Income (Loss), Net of Tax $139,000 USD 256%
Retained Earnings (Accumulated Deficit) $329,999,000 USD -5%
Stockholders' Equity Attributable to Parent $157,168,000 USD 128%
Liabilities and Equity $167,017,000 USD 95%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $11,864,000 USD 40%
Net Cash Provided by (Used in) Financing Activities $10,000 USD -225%
Net Cash Provided by (Used in) Investing Activities $115,498,000 USD 994%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 47,128,362 shares 91%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $198,835,000 USD
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD -100%
Deferred Tax Assets, Valuation Allowance $121,898,000 USD 69%
Operating Lease, Liability $0 USD -100%
Depreciation $131,600 USD -41%
Payments to Acquire Property, Plant, and Equipment $551,000 USD -25%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $15,518,000 USD 75%
Lessee, Operating Lease, Liability, to be Paid $940,000 USD -35%
Property, Plant and Equipment, Gross $377,000 USD -94%
Operating Lease, Liability, Current $0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two $231,000 USD -28%
Lessee, Operating Lease, Liability, to be Paid, Year One $320,000 USD -38%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $107,000 USD -42%
Lessee, Operating Lease, Liability, to be Paid, Year Three $280,000 USD 21%
Deferred Tax Assets, Operating Loss Carryforwards $49,184,000 USD 13%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $5,371,000 USD 17%
Lessee, Operating Lease, Liability, to be Paid, Year Four $109,000 USD -61%
Operating Lease, Payments $99,000 USD -21%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $50,000 USD 32%
Deferred Tax Assets, Net of Valuation Allowance $390,000 USD -30%
Interest Expense $231,000 USD 0.44%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%